"The U.S. Food and Drug Administration today approved Zerbaxa (ceftolozane/tazobactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).
Neggram Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
NegGram (nalidixic acid, USP) Oral Suspension is a quinolone antibiotic used to treat urinary tract infections. It is available in generic form. Common side effects of NegGram include drowsiness, weakness, headache, dizziness, vertigo, abdominal pain, nausea, vomiting, diarrhea, and rash.
The recommended dosage of NegGram is 1 gram taken four times a day for one or two weeks, and 2 grams per day thereafter. Warfarin, tetracycline, chloramphenicol, nitrofurantoin, probenecid, melphalan, didanosine, and cyclosporine may interact with NegGram. Do not stop taking NegGram unless directed by your doctor. Avoid excess sunlight while taking NegGram. Do not drive, use machinery, or do other activity requiring full alertness while using NegGram. If you are pregnant only take NegGram if the potential benefit outweighs the potential risk to the fetus. Do not take NegGram if you are breastfeeding.
Our NegGram (nalidixic acid, USP) Oral Suspension Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Neggram FDA Prescribing Information: Side Effects
Reactions reported after oral administration of NegGram include the following.
drowsiness, weakness, headache, dizziness and vertigo. Reversible subjective visual disturbances without objective findings have occurred infrequently (generally with each dose during the first few days of treatment). These reactions include overbrightness of lights, change in color perception, difficulty in focusing, decrease in visual acuity, and double vision. They usually disappeared promptly when dosage was reduced or therapy was discontinued. Toxic psychosis or brief convulsions have been reported rarely, usually following excessive doses. In general, the convulsions have occurred in patients with predisposing factors such as epilepsy or cerebral arteriosclerosis. In infants and children receiving therapeutic doses of NegGram, increased intracranial pressure with bulging anterior fontanel, papilledema, and headache has occasionally been observed. A few cases of 6th cranial nerve palsy have been reported. Although the mechanisms of these reactions are unknown, the signs and symptoms usually disappeared rapidly with no sequelae when treatment was discontinued.
rash, pruritus, urticaria, angioedema, eosinophilia, arthralgia with joint stiffness and swelling, and anaphylactoid reaction, including anaphylactic shock. Erythema Multiforme and Stevens-Johnson syndrome have been reported with nalidixic acid and other drugs in this class. Rash was the most frequently reported adverse reaction. Photosensitivity reactions consisting of erythema and bullae on exposed skin surfaces usually resolve completely in 2 weeks to 2 months after NegGram is discontinued; however, bullae may continue to appear with successive exposures to sunlight or with mild skin trauma for up to 3 months after discontinuation of drug. (See PRECAUTIONS.)
rarely, cholestasis, paresthesia, metabolic acidosis, thrombocytopenia, leukopenia, or hemolytic anemia, sometimes associated with glucose 6-phosphate dehydrogenase deficiency and peripheral neuropathy.
Read the entire FDA prescribing information for Neggram (Nalidixic Acid)
Additional NegGram Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.